Co-Diagnostics Inc., of Salt Lake City, closed a nonconvertible debt instrument of $2 million that it plans to use for working capital, to expand distribution of its infectious disease testing products and to accelerate its plan to develop multiplex screens for liquid biopsy cancer screening, blood-bank screening and SNP detection.